White House targets blockbusters in Medicare’s price negotiation strategy

Photo by Tabrez Syed on Unsplash

The Biden-Harris Administration has nominated 10 drugs for price negotiations directly with pharmaceutical giants after capping monthly insulin costs at $35.

Americans have historically paid more for prescription drugs than most other major economies. In a fact sheet, the White House highlighted that seniors paid $3.4 billion in out-of-pocket costs for these drugs just last year. Biden, like Trump before him, aim to bring prices more in line with those of other advanced nations.

This move is not isolated. The Biden Administration has implemented other cost-saving measures, such as reining in the cost of insulin and making some vaccines free for Medicare beneficiaries.

All of the 10 drugs on the list were blockbusters. Eight of the 10 were among the bestselling drugs of 2022. The remaining two are insulin formulations from Novo Nordisk: Fiasp and NovoLog.

Read more
  • 0

Exploring Merck’s key arguments in its constitutional challenge against the Inflation Reduction Act

In a strong move against the federal government, Merck & Co., based in Kenilworth, New Jersey, has launched a lawsuit against the Inflation Reduction Act (IRA). The firm has retained the services of prominent law firm Jones Day, at times known for its assertive litigation style. In recent years, the firm has also been involved in contentious cases, for instance, representing Volkswagen in its emissions scandal and Donald Trump during his presidential campaigns. In Merck’s opening salvo against the government’s prescription drug pricing program under the Inflation Reduction Act (IRA), the company has fired off a strongly-worded complaint. The suit was filed on June 6 in the U.S. District Court for the District of Columbia against senior federal healthcare officials and agencies including the Secretary of Health and Human Services Xavier Becerra, and the Centers for Medicare & Medicaid Services.

This legal challenge is the latest chapter in Merck’s…

Read more
  • 0